Field Application Engineer
About Paradromics
Brain-related illness is one of the last great frontiers in medicine, not because the brain is unknowable, but because it has been inaccessible. Paradromics is building a brain-computer interface (BCI) platform that records brain activity at the highest possible resolution: the individual neuron. AI algorithms then decode this massive amount of brain data, enabling the seamless translation of thought into treatments.
Our first clinical application, the Connexus® BCI, will help people who are unable to speak due to progressive neuromuscular disease and neural injuries such as ALS, spinal cord injuries, and stroke to communicate independently through digital devices. However, the capabilities of our BCI platform go far beyond our first application. With the brain in direct communication with digital devices, we can leverage technology to transform how we treat conditions ranging from sensory and motor deficits to untreatable mental illness.
The Field Application Engineer serves as Paradromics’s technical lead for bringing scientific innovations and new BCI applications into the field. A core focus of this role is reducing R&D to practice, and ensuring that real-world clinical learnings are documented, clearly communicated, and translated into system, process, and risk-management improvements. Reporting to the Principal Applied Scientist, this field-based role acts as a critical bridge between the field and engineering teams. The position requires significant travel to clinical sites and the ability to operate independently in high-stakes, participant-facing environments.
Paradromics is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, or national origin.

ENABLING NEUROTECHNOLOGY
Paradromics builds brain-computer interface (BCI) technologies for seamless human-technology integration, designed to restore and enhance human capabilities. By capturing brain activity at the resolution of individual neurons, our high-data-rate platform creates a foundation for the most advanced BCI applications. With each new application, we will create human capabilities that transcend disabilities, and eventually, biology itself.
THE MISSION
Data-driven BCI-based technologies for brain health
Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions.
ABOUT
Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI.
Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics achieved its first human implantation of the Connexus BCI as part of the FDA-approved Connect-One study in June 2026, marking a major milestone toward delivering its first product to people living with severe motor impairment.